Neurocrine Biosciences (LTS:0K6R) Total Liabilities : $1,129 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Neurocrine Biosciences Total Liabilities?

Neurocrine Biosciences's Total Liabilities for the quarter that ended in Dec. 2024 was $1,129 Mil.

Neurocrine Biosciences's quarterly Total Liabilities increased from Jun. 2024 ($795.80 Mil) to Sep. 2024 ($816.10 Mil) and increased from Sep. 2024 ($816.10 Mil) to Dec. 2024 ($1,129.00 Mil).

Neurocrine Biosciences's annual Total Liabilities increased from Dec. 2022 ($660.90 Mil) to Dec. 2023 ($1,019.40 Mil) and increased from Dec. 2023 ($1,019.40 Mil) to Dec. 2024 ($1,129.00 Mil).

Neurocrine Biosciences Total Liabilities Historical Data

The historical data trend for Neurocrine Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Total Liabilities Chart

Neurocrine Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

608.50

698.50

660.90

1,019.40

1,129.00

Neurocrine Biosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															1,019.40	1,086.30	795.80	816.10	1,129.00

Neurocrine Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Neurocrine Biosciences's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	507.7	+	(455.1	+	5.4999999999999
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	160.7)
	=	1,129

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	3718.7	-	2589.7
	=	1,129

Neurocrine Biosciences's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	507.7	+	(455.1	+	5.4999999999999
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	160.7)
	=	1,129

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	3718.7	-	2589.7
	=	1,129

Neurocrine Biosciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurocrine Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (LTS:0K6R) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

NBIX:USA NB3:Germany N1BI34:Brazil

Address

6027 Edgewood Bend Court, San Diego, CA, USA, 92130

Website

https://www.neurocrine.com

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Neurocrine Biosciences Headlines

No Headlines